NCT04497883View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Maribavir Administered in Healthy Japanese Participants Compared With Matched, Healthy, Non-Hispanic, Caucasian Participants and to Assess Dose-Proportionality of 3 Doses of Maribavir in Japanese Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 7, 2020

Primary Completion Date

November 12, 2020

Study Completion Date

November 12, 2020

Conditions

Healthy Volunteers

Interventions

DRUG

Maribavir (400 mg)

Non-Hispanic, Caucasian group and Japanese descent group participants will receive 400 mg maribavir tablets orally once on Day 1 during treatment period 1.

DRUG

Maribavir (200 mg)

Japanese descent group participants will receive 200 mg maribavir tablets orally once on Day 1 during treatment period 2 or 3.

DRUG

Maribavir (800 mg)

Japanese descent group participants will receive 800 mg maribavir tablets orally once on Day 1 during treatment period 2 or 3.

Trial Locations (1)

89113

PPD Development, LP, Las Vegas